Literature DB >> 23258898

Toward victory in adult ALL: blinatumomab joins in.

Renato Bassan1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23258898     DOI： 10.1182/blood-2012-10-460394

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

Review 1.  Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Authors:  Emily Curran; Wendy Stock
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

Review 2.  Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.

Authors:  Josep-Maria Ribera; Albert Ferrer; Jordi Ribera; Eulàlia Genescà
Journal:  Onco Targets Ther       Date:  2015-06-24       Impact factor: 4.147

3.  Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.

Authors:  Dalma Deak; Cristina Pop; Alina-Andreea Zimta; Ancuta Jurj; Alexandra Ghiaur; Sergiu Pasca; Patric Teodorescu; Angela Dascalescu; Ion Antohe; Bogdan Ionescu; Catalin Constantinescu; Anca Onaciu; Raluca Munteanu; Ioana Berindan-Neagoe; Bobe Petrushev; Cristina Turcas; Sabina Iluta; Cristina Selicean; Mihnea Zdrenghea; Alina Tanase; Catalin Danaila; Anca Colita; Andrei Colita; Delia Dima; Daniel Coriu; Hermann Einsele; Ciprian Tomuleasa
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

Review 4.  Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Authors:  Jingjing Wu; Jiaping Fu; Mingzhi Zhang; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

5.  Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.

Authors:  Thomas Köhnke; Christina Krupka; Johanna Tischer; Thomas Knösel; Marion Subklewe
Journal:  J Hematol Oncol       Date:  2015-10-08       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.